| Literature DB >> 34564154 |
Wencong Yang1, Qi Tan1, Yihao Yin1, Yan Chen1,2, Yi Zhang3, Jianying Wu1, Leyao Gao1, Bo Wang1, Zhigang She1.
Abstract
Eight new compounds, including two sambutoxin derivatives (1-2), two highly oxygenated cyclopentenones (7-8), four highly oxygenated cyclohexenones (9-12), together with four known sambutoxin derivatives (3-6), were isolated from semimangrove endophytic fungus Talaromyces sp. CY-3, under the guidance of molecular networking. The structures of new isolates were elucidated by analysis of detailed spectroscopic data, ECD spectra, chemical hydrolysis, 13C NMR calculation, and DP4+ analysis. In bioassays, compounds 1-5 displayed better α-glucosidase inhibitory activity than the positive control 1-deoxynojirimycin (IC50 = 80.8 ± 0.3 μM), and the IC50 value was in the range of 12.6 ± 0.9 to 57.3 ± 1.3 μM.Entities:
Keywords: Talaromyces sp.; molecular networking; polyketides; sambutoxin; α-glucosidase
Mesh:
Substances:
Year: 2021 PMID: 34564154 PMCID: PMC8465095 DOI: 10.3390/md19090492
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Clusters of nodes from Talaromyces sp. for compounds 1–3, 5, 8, and 10–12.
Figure 2Structure of compounds 1–12.
1H NMR and 13C NMR of 1–3.
| NO. | 1 (CDCl3) | 2 (CDCl3) | 3 (CDCl3) | |||
|---|---|---|---|---|---|---|
| 2 | 161.5, C | 161.7, C | 162.7, C | |||
| 3 | 110.4, C | 110.1, C | 110.4, C | |||
| 4 | 162.0, C | 162.5, C | 162.4, C | |||
| 5 | 115.2, C | 115.4, C | 115.9, C | |||
| 6 | 136.4, CH | 7.14, s | 136.2, CH | 7.11, s | 136.0, CH | 7.12, s |
| 7 | 78.0, CH | 5.02, d, (9.1) | 73.7, CH | 5.17, dd, (10.5, 3.1) | 77.8, CH | 5.02, d, (9.0) |
| 8 | 30.8, CH2 | 1.64–1.69, m, 2.09, d, (11.4) | 29.9, CH2 | 1.25–1.31, m, 2.25–2.35, m | 30.9, CH2 | 1.64–1.70, m, 2.09, d, (11.4) |
| 9 | 32.3, CH2 | 1.44, d, (10.1) 1.91, d, (13.1) | 121.9, CH | 5.72, d, (5.2) | 32.2, CH2 | 1.44, d, (10.1) 1.91, d, (13.1) |
| 10 | 32.5, CH | 1.64–1.69, m | 132.9, C | 32.1, CH | 1.64–1.70, m | |
| 11 | 92.7, CH | 3.53, s | 86.9, CH | 4.56, s | 92.7, CH | 3.53, s |
| 12 | 130.4, C | 130.2, C | 130.3, C | |||
| 13 | 138.1, CH | 5.18, d, (9.5) | 139.7, CH | 5.29, d, (9.6) | 138.1, CH | 5.18, d, (9.5) |
| 14 | 29.7, CH | 2.42–2.49, m | 30.0, CH | 2.40–2.50, m | 29.7, CH | 2.42–2.49, m |
| 15 | 44.8, CH2 | 1.01–1.07, m 1.16–1.21, m | 44.8, CH2 | 1.01–1.04, m, 1.25–1.31, m | 44.8, CH2 | 1.01–1.07, m 1.16–1.21, m |
| 16 | 32.1, CH | 1.29–1.35, m | 32.2, CH | 1.25–1.31, m | 32.4, CH | 1.29–1.34, m |
| 17 | 29.0, CH2 | 1.01–1.07, m 1.29–1.35, m | 29.0, CH2 | 1.01–1.04, m, 1.25–1.31, m | 29.0, CH2 | 1.01–1.07, m 1.29–1.34, m |
| 18 | 11.3, CH3 | 0.83, s | 11.0, CH3 | 1.53, d, (1.3) | 11.3, CH3 | 0.83, s |
| 19 | 19.7, CH3 | 0.82, d, (6.5) | 20.8, CH3 | 0.90, d, (6.6) | 19.7, CH3 | 0.82, d, (6.5) |
| 20 | 20.8, CH3 | 0.90, d, (6.6) | 19.7, CH3 | 0.82, d, (6.4) | 20.8, CH3 | 0.90, d, (6.6) |
| 21 | 11.7, CH3 | 1.61, s | 11.3, CH3 | 1.49, s | 11.7, CH3 | 1.61, s |
| 22 | 17.8, CH3 | 0.74, d, (6.5) | 19.1, CH3 | 0.81, s | 17.7, CH3 | 0.74, d, (6.5) |
| 23 | 37.2, CH3 | 3.50, s | 37.3, CH3 | 3.50, s | 37.4, CH3 | 3.50, s |
| 1′ | 134.2, C | 125.9, C | 125.2, C | |||
| 2′ | 129.3, CH | 7.35–7.44, m | 130.6, CH | 7.26, d, (9.0) | 130.5, CH | 7.26, d, (9.0) |
| 3′ | 128.4, CH | 7.35–7.44, m | 115.5, CH | 6.87, d, (8.1) | 115.6, CH | 6.92, d, (8.1) |
| 4′ | 127.5, CH | 7.29–7.34, m | 155.8, C | 156.5, C | ||
| 5′ | 128.4, CH | 7.35–7.44, m | 115.5, CH | 6.87, d, (8.1) | 115.6, CH | 6.92, d, (8.1) |
| 6′ | 129.3, CH | 7.35–7.44, m | 130.6, CH | 7.26, d, (9.0) | 130.5, CH | 7.26, d, (9.0) |
| 4′-OH | 9.99, s | 9.83, s | 9.83, s | |||
Figure 3HMBC (red arrow) and key COSY (blue bold line) of 1–2 and 7–12.
Figure 4NOESY correlations of 1–2 and 7–12.
Figure 5ECD spectra of compounds 1 (A), 2 (B), 7 (C), 8 (D), 9 (E), 10 (F), 11 (G) and 12 (H) in CH3OH.
1H NMR of 7–12.
| Position | 7 | 8 | 9 | 10 | 11 | 12 |
|---|---|---|---|---|---|---|
| 3 | 4.98, s | 5.10, q, (6.3) | 3.51, d, (9.5) | 3.40, d, (7.2) | 3.80, d, (3.2) | |
| 4 | 2.55, dqd, (11.3, 6.8, 1.7) | 2.77–2.83, m | 3.02, qdd, (7.1, 3.2, 1.9) | |||
| 5 | 5.55, s | |||||
| 6 | 1.30, s | 1.42, s | 1.29, d, (6.4) | 5.30, d, (1.7) | 5.33, d, (1.2) | 5.34, d, (1.9) |
| 7 | 4.16, s | 3.98, s | 4.10, s | 1.28, d, (6.8) | 1.30, d, (7.2) | 1.27, d, (7.1) |
| 8 | 1.67, s | 1.56, t, (1.8) | 1.22, s | 1.34, s | 1.30, s | |
| 9 | 2.20, s | 3.75, s | 3.76, s | 3.75, s | ||
| 10 | 2.37, q, (7.0) | 2.19–2.28, m | ||||
| 11 | 1.44–1.50, m 1.58–1.65, m | 1.34–1.40, m 1.44–1.50, m | ||||
| 12 | 0.94, t, (7.5) | 0.80, t, (7.5) | ||||
| 13 | 1.12, d, (7.0) | 1.02, d, (7.0) | ||||
| 14 | 2.82, dq, (18.2, 1.8) 3.03, dq, (18.2, 1.8) | |||||
| 15 | 3.16, s |
13C NMR of 7–12.
| Position | 7 | 8 | 9 | 10 | 11 | 12 |
|---|---|---|---|---|---|---|
| 1 | 202.0 | 200.6 | 205.0 | 203.0 | 200.9 | 203.3 |
| 2 | 86.4 | 80.4 | 84.3 | 78.4 | 75.5 | 77.7 |
| 3 | 73.5 | 92.5 | 71.7 | 78.1 | 78.7 | 79.0 |
| 4 | 179.7 | 192.4 | 188.2 | 41.5 | 40.1 | 39.0 |
| 5 | 115.6 | 103.3 | 117.5 | 180.1 | 180.5 | 178.9 |
| 6 | 19.5 | 23.5 | 14.9 | 99.5 | 99.6 | 99.0 |
| 7 | 59.1 | 60.1 | 58.2 | 14.0 | 14.2 | 13.4 |
| 8 | 6.08 | 207.2 | 5.6 | 19.2 | 21.4 | 23.6 |
| 9 | 177.5 | 27.5 | 176.4 | 57.2 | 57.0 | 57.1 |
| 10 | 42.0 | 42.4 | ||||
| 11 | 27.8 | 27.8 | ||||
| 12 | 11.8 | 11.7 | ||||
| 13 | 16.8 | 16.6 | ||||
| 14 | 31.2 | |||||
| 15 | 51.8 |
Figure 6Confirmation for C-10 of compounds 7 and 9 through chemical hydrolysis.
Figure 7Proposed biogenetic pathways of 1–2 (A) and 7–12 (B).
α-glucosidase inhibitory activity for 1–12.
| Compounds | IC50/μM | Compounds | IC50/μM |
|---|---|---|---|
|
| 12.6 ± 0.9 |
| >100 |
|
| 37.4 ± 1.4 |
| >100 |
|
| 16.9 ± 0.6 |
| >100 |
|
| 16.5 ± 0.7 |
| >100 |
|
| 57.3 ± 1.3 |
| >100 |
|
| >100 |
| >100 |
| 1-deoxynojirimycin | 80.8 ± 0.3 |
Figure 8Binding mode of sambutoxins 1 (A), 2 (B), 3 (C), 4 (D), and 5 (E) with α-glucosidase.